

Gordon Research Conferences

Meeting Details

Home

Conferences

- Current Meetings (2017)
- Upcoming Meetings (2018)
- Past Meetings
- Gordon Research Seminars
- Conference Portfolio
- Proposing a New Gordon Conference

For Attendees

The GRC Organization

Search:

GO

Tuberculosis Drug Discovery & Development Gordon Research Conference

Gordon Roddaron Gomerened

New Approaches, New Chemical Entities and New Targets for Tuberculosis Drugs

Dates

June 25-30, 2017

Location

Renaissance Tuscany II Ciocco Lucca (Barga), Italy

Site Information

Organizers

Chairs:

Courtney C. Aldrich & Tanya Parish

Vice Chairs:

Lluis Ballell-Pages & Helena I. Boshoff

Meeting Links

- Online Application
- Conference History
- Contact Chairs
- Registration Information

Site & Travel Links

Registration Fees

Follow us on Facebook

Application Deadline

This meeting is currently oversubscribed (full). You may still submit an application. However, it will only be considered by the Conference Chair if more seats become available due to cancellations.

Meeting Description

The 2017 Conference on Tuberculosis Drug Discovery and Development will explore the entire process of drug discovery from clinical development of new drugs for tuberculosis (TB) to the underlying biology of *Mycobacterium tuberculosis* that impacts drug discovery efforts. The conference will address the unique challenges in TB drug discovery through discussion of clinical trial design, complimentary approaches to identification of lead compounds, vulnerable targets and pathways, host-directed therapies, and non-traditional approaches to TB prevention and treatment. We invite researchers interested in all aspects of drug discovery and development and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from TB-endemic countries to apply, as their contribution to the struggle against TB is especially important. All participants are asked to submit abstracts of their work for presentation as posters, and some abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote extensive discussion. In the past, the meeting has been oversubscribed – please apply early!

Related Meeting



This GRC will be held in conjunction with the "Tuberculosis Drug Discovery & Development" Gordon Research Seminar (GRS). Those interested in attending both meetings must submit an application for the GRS in addition to an application for the GRC. Refer to the associated GRS program page for more information.

Contributors







 $https://www.grc.org/programs.aspx?id{=}13038[21{-}05{-}2017\ 22{:}38{:}15]$















Meeting Program

Sunday	
4:00 pm - 8:00 pm	Arrival and Check-in
6:00 pm	Dinner
7:30 pm - 7:40 pm	Welcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pm	Keynote Session: The Need for New Drugs Against Tuberculosis
	Discussion Leader: Tanya Parish (Infectious Disease Research Institute, USA)
7:40 pm - 7:50 pm	Opening Remarks
7:50 pm - 8:00 pm	Introduction by Discussion Leader
8:00 pm - 8:40 pm	Graeme Meintjes (University of Cape Town, South Africa) "New Drugs for TB: Clinical and Programmatic Needs and Challenges"
8:40 pm - 8:45 pm	Discussion
8:45 pm - 9:25 pm	Valerie Mizrahi (Institute of Infectious Disease and Molecular Medicine, South Africa) "Harnessing Biological Insight to Accelerate TB Drug Discovery"
9:25 pm - 9:30 pm	Discussion
Monday	
7:30 am - 8:30 am	Breakfast
9:00 am - 12:30 pm	Challenges in Clinical Trials and Biomarkers for Tuberculosis
	Discussion Leader: Anna Upton (TB Alliance, USA)
9:00 am - 9:05 am	Introduction by Discussion Leader
9:05 am - 9:30 am	Bruce Thomas (The Arcady Group, USA) "New Facts Regarding, and Novel Approaches to, TB Treatment Adherence: Implications for Clinical Practice and Drug Development"
9:30 am - 9:40 am	Discussion
9:40 am - 10:05 am	Gerhard Walzl (Stellenbosch University, South Africa) "Developing Treatment Response Biomarkers"
10:05 am - 10:15 am	Discussion
10:15 am - 10:40 am	Coffee Break
10:40 am - 11:05 am	Debra Hanna (Critical Path Institute, USA) "Critical Path to TB Drug Regimens: Integrating Data to Drive Innovation in Translational Science for TB Drug Regimen Development"
11:05 am - 11:15 am	Discussion
11:15 am - 11:40 am	Gerry Davies (University of Liverpool, United Kingdom) "PreDiCT-TB: Learning from Preclinical Data"
11:40 am - 11:50 am	Discussion
11:50 am - 12:15 pm	Rada Savic (University of California, San Fransisco, USA)

	"One Treatment Regimen Does Not Fit All - Use of Data Science to Guide TB Patient Stratification"
12:15 pm - 12:25 pm	Ç
12:25 pm - 12:30 pm	
12:30 pm	Lunch
1:30 pm - 4:30 pm	Free Time
4:30 pm - 6:00 pm	Poster Session
6:00 pm - 8:00 pm	Lead Optimization and Clinical Evaluation
	Discussion Leader: Lluis Ballell-Pages (GlaxoSmithKline, Spain)
6:00 pm - 6:05 pm	Introduction by Discussion Leader
6:05 pm - 6:30 pm	Nader Fotouhi (TB Alliance, USA)
	"Towards Safer Oxazolidinones as Components of Universal Regimens for TB"
6:30 pm - 6:40 pm	Discussion
6:40 pm - 7:05 pm	Vadim Makarov (A.N. Bach Institute of Biochemistry, Russian Academy of Sciences, Russia) "Clinical Trials with the Novel Drug Candidate PBTZ169"
7:05 pm - 7:15 pm	Discussion
7:15 pm - 7:40 pm	David Barros (GlaxoSmithKline R&D, Spain) "New Clinical Candidates for TB Treatment"
7:40 pm - 7:50 pm	Discussion
7:50 pm - 8:00 pm	General Discussion
8:00 pm	Dinner
Tuesday	
7:30 am - 8:30 am	Breakfast
8:30 am	Group Photo
9:00 am - 12:30 pm	Hit-to-Lead Optimization and Pharmacokinetics in Early Drug Discovery
	Discussion Leader: Kelly Chibale (Institute of Infectious Disease and Molecular Medicine, South Africa)
9:00 am - 9:10 am	Introduction by Discussion Leader
9:10 am - 9:35 am	Jeffrey Aube (University of North Carolina at Chapel Hill, USA) "Seeking TB-Active Cephalosporins"
9:35 am - 9:45 am	Discussion
9:45 am - 10:10 am	Sylvie Garneau-Tsodikova (University of Kentucky, USA) "Novel Aminoglycoside Adjuvants and Stand-Alone Agents to Combat Tuberculosis"
10:10 am - 10:20 am	Discussion
10:20 am - 10:50 am	Coffee Break
10:50 am - 11:15 am	Jason Sello (Brown University, USA) "Beyond the Conventional: Novel Molecules and Strategies for the Treatment of Tuberculosis"
11:15 am - 11:25 am	Discussion
11:25 am - 11:50 am	Benoit Deprez (Institut Pasteur, France) "Outsmarting Resistance in Tuberculosis SMARt Compounds: From Lead to Drug Candidate"
11:50 am - 12:00 pm	Discussion
12:00 pm - 12:15 pm	Short Talk Selected from Poster Abstracts
12:15 pm - 12:20 pm	Discussion
12:20 pm - 12:30 pm	General Discussion
12:30 pm	Lunch
1:30 pm - 4:30 pm	Free Time
4:30 pm - 6:00 pm	Poster Session
6:00 pm - 8:00 pm	Natural Products in Antibacterial Discovery
	Discussion Leader: Ronald Quinn (Griffith University, Australia)
6:00 pm - 6:05 pm	Introduction by Discussion Leader

6:05 pm - 6:30 pm	Sean Brady (Rockefeller University, USA) "Culture Independent Approaches for the Discovery of New Antibiotics"
6:30 pm - 6:40 pm	Discussion
6:40 pm - 7:05 pm	Late-Breaking Topic
7:05 pm - 7:15 pm	Discussion
7:15 pm - 7:40 pm	Nathan Magarvey (McMaster University, Canada) "Clustering and Assembly of Genetically Inferred Antibiotics"
7:40 pm - 7:50 pm	Discussion
7:50 pm - 8:00 pm	General Discussion
8:00 pm	Dinner
Wednesday	
7:30 am - 8:30 am	Breakfast
9:00 am - 12:30 pm	Metabolism as a Target
	Discussion Leader: Luiz Pedro Carvalho (Francis Crick Institute, United Kingdom)
9:00 am - 9:05 am	Introduction by Discussion Leader
9:05 am - 9:35 am	Laura Kiessling (University of Wisconsin-Madison, USA) "Chemical Probes of Cell Envelope Biosynthesis"
9:35 am - 9:45 am	Discussion
9:45 am - 10:10 am	Lindsay Eltis (University of British Columbia, Canada) "Cholesterol Catabolism - A Ring-Side Seat"
10:10 am - 10:20 am	Discussion
10:20 am - 10:50 am	Coffee Break
10:50 am - 11:15 am	Anthony Baughn (University of Minnesota, USA) "Stress Response as a Driver of Pyrazinamide Susceptibility"
11:15 am - 11:25 am	Discussion
11:25 am - 11:50 am	Nagasuma Chandra (Indian Institute of Science, India) "Reversing Antibiotic Resistance Through Strategic Combinations"
11:50 am - 12:00 pm	Discussion
12:00 pm - 12:15 pm	Short Talk Selected from Poster Abstracts
12:15 pm - 12:20 pm	Discussion
12:20 pm - 12:30 pm	General Discussion
12:30 pm	Lunch
1:30 pm - 4:30 pm	Free Time
4:30 pm - 6:00 pm	Poster Session
6:00 pm - 8:00 pm	Promiscuous Targets, Drugs, and Hits
	Discussion Leader: Kevin Pethe (Lee Kong Chian School of Medicine, Nanyang Technologicial University, Singapore)
6:00 pm - 6:05 pm	Introduction by Discussion Leader
6:05 pm - 6:30 pm	Jonathan Baell (Monash University, Australia) "Resource-Wasting Pan Assay Interference Compounds (PAINS): Readily Found in Any Screen and Highly Relevant to TB Drug Discovery"
6:30 pm - 6:35 pm	Discussion
6:35 pm - 6:50 pm	Short Talk Selected from Poster Abstracts
6:50 pm - 6:55 pm	Discussion
6:55 pm - 7:20 pm	Adrie Steyn (Kwazulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), South Africa) "Bioenergetic Rewiring: Turning the Respiratory Flexibility of <i>M. tuberculosis</i> Against Itself"
7:20 pm - 7:25 pm	Discussion
7:25 pm - 7:50 pm	Mary Jackson (Colorado State University, USA) "MmpL3: Therapeutic Potential and Mechanism of Inhibition"
7:50 pm - 7:55 pm	Discussion

7:55 pm - 8:00 pm	General Discussion
8:00 pm	Dinner
Thursday	
7:30 am - 8:30 am	Breakfast
8:30 am - 9:00 am	Business Meeting
	Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
9:00 am - 12:30 pm	Host-Directed Therapies and Host-Pathogen Interactions
	Discussion Leader: Gilla Kaplan (Bill & Melinda Gates Foundation, USA)
9:00 am - 9:10 am	Introduction by Discussion Leader
9:10 am - 9:35 am	Priscille Brodin (Institut Pasteur de Lille, France) "Investigation of a Drug Candidate with Enhanced Potency Against Intracellular <i>M. tuberculosis</i> "
9:35 am - 9:45 am	Discussion
9:45 am - 10:10 am	Robert Abramovitch (Michigan State University, USA) "Small Molecules that Inhibit Mycobacterium tuberculosis Environmental Sensing and Virulence"
10:10 am - 10:20 am	Discussion
10:20 am - 10:50 am	Coffee Break
10:50 am - 11:05 am	Short Talk Selected from Poster Abstracts
11:05 am - 11:10 am	Discussion
11:10 am - 11:35 am	Late-Breaking Topic
11:35 am - 11:45 am	Discussion
11:45 am - 12:10 pm	Thomas Hawn (University of Washington, USA) "Host-Directed Therapies in Macrophages and TB"
12:10 pm - 12:20 pm	Discussion
12:20 pm - 12:30 pm	General Discussion
12:30 pm	Lunch
1:30 pm - 4:30 pm	Free Time
4:30 pm - 6:00 pm	<u>Poster Session</u>
6:00 pm - 8:00 pm	Outside the Norm: Non-Traditional Approaches
	Discussion Leader: Helena Boshoff (National Institutes of Health, USA)
6:00 pm - 6:05 pm	Introduction by Discussion Leader
6:05 pm - 6:30 pm	Late-Breaking Topic
6:30 pm - 6:40 pm	Discussion
6:40 pm - 7:05 pm	Nitin Baliga (Institute for Systems Biology, USA) "Network Strategy to Accelerate Discovery of Combination Therapy Against Drug Resistance in TB"
7:05 pm - 7:15 pm	Discussion
7:15 pm - 7:40 pm	Giulia Manina (Institut Pasteur, France) "Targeting Phenotypic Variation in Mycobacteria to Improve Drug-Mediated Killing"
7:40 pm - 7:50 pm	Discussion
7:50 pm - 8:00 pm	Closing Remarks
8:00 pm	Dinner
Friday	
7:30 am - 8:30 am	Breakfast
9:00 am	Departure

Funding for this conference was made possible [in part] by 1 R13 Al 131575 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

★ Back to Top

© 2017 Gordon Research Conferences

Search | Contact | Terms of Use | Privacy Policy | Follow us: